Utility of Mesenchymal Stem Cell Therapy in Type 1 Diabetes

Chapter
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 6)

Abstract

Clinical trials are underway to test the therapeutic efficacy of mesenchymal stem cells (MSCs) in a number of diseases with no curative therapy available, including type 1 diabetes mellitus (T1D). Due to their plasticity, MSCs first gained interest in cell-based tissue engineering; however, given their low immunogenicity and profound immunodulatory effects, MSCs are now receiving much attention as a cell-based therapy for immune-mediated disorders. The use of MSCs in T1D holds potential in three different disciplines: systemic injection of MSCs to suppress autoreactive T cells; co-transplantation with islet allografts to enhance islet engraftment in an immuno-privileged microenvironment; and differentiation of MSCs into insulin-producing cells (IPC). We are focusing on the potential translation of MSCs therapy for clinical development to treat T1D.

Keywords

Beta Cell Islet Cell Program Death Ligand Insulin Produce Cell Metachromatic Leukodystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

BM

Bone marrow

GVHD

Graft-versus-host disease

HSCs

Hematopoietic stem cells

hBM-MSC

Human bone marrow-derived MSC

IPC

Insulin-producing cells

MSCs

Mesenchymal stem cells

T1D

Type 1 diabetes

STZ

Streptozoticin

UBC

Umbilical cord blood

UC

Umbilical cord tissue

References

  1. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35:1482–1490PubMedCrossRefGoogle Scholar
  2. Baertschiger RM, Bosco D, Morel P, Serre-Beinier V, Berney T, Buhler LH, Gonelle-Gispert C (2008) Mesenchymal stem cells derived from human exocrine pancreas express transcription factors implicated in beta-cell development. Pancreas 37:75–84PubMedCrossRefGoogle Scholar
  3. Berman DM, Willman MA, Han D, Kleiner G, Kenyon NM, Cabrea O, Karl JA, Wiseman RW, O’Connor DH, Bartholomew AM, Kenyon NS (2010) Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes 59:2558–2568PubMedCrossRefGoogle Scholar
  4. Carlotti F, Zaldumbide A, Loomans CJ, van Rossenberg E, Engelse M, de Koning EJ, Hoeben RC (2010) Isolated human islets contain a distinct population of mesenchymal stem cells. Islets 2:164–173PubMedCrossRefGoogle Scholar
  5. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, Anegon I, Cuturi MC (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110:3691–3694PubMedCrossRefGoogle Scholar
  6. Chao KC, Chao KF, Fu YS, Liu SH (2008) Islet-like clusters derived from mesenchymal stem cells in Wharton’s Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS One 3:e1451PubMedCrossRefGoogle Scholar
  7. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC (2005) Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24:458–463PubMedCrossRefGoogle Scholar
  8. DIAMOND Project Group (2006) Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet Med 23:857–866CrossRefGoogle Scholar
  9. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ (2009) Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 58:1797–1806PubMedCrossRefGoogle Scholar
  10. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA (2008) Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 14:631–640PubMedCrossRefGoogle Scholar
  11. Figliuzzi M, Cornolti R, Perico N, Rota C, Morigi M, Remuzzi G, Remuzzi A, Benigni A (2009) Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant Proc 41:1797–1800PubMedCrossRefGoogle Scholar
  12. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R (2009) Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183:993–1004PubMedCrossRefGoogle Scholar
  13. Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka BM (2004) Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306:2261–2264PubMedCrossRefGoogle Scholar
  14. Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J, Nair I, Ferreri K, Kandeel F, Mullen Y (2010) Mesenchymal stem cells and islet co-transplantation promotes graft revascularization and function. Transplantation 12:1438–1445CrossRefGoogle Scholar
  15. Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, Fiorina P, Atkinson M, Sayegh MH, Abdi R (2010) Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59:3139–3147PubMedCrossRefGoogle Scholar
  16. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S (2007) Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells 25:2837–2844PubMedCrossRefGoogle Scholar
  17. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722–3729PubMedCrossRefGoogle Scholar
  18. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20PubMedCrossRefGoogle Scholar
  19. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103:17438–17443PubMedCrossRefGoogle Scholar
  20. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103:4619–4621PubMedCrossRefGoogle Scholar
  21. Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499–3506PubMedCrossRefGoogle Scholar
  22. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE (2006) Mesenchymal stem cells inhibit generation and function of both CD34+ -derived and monocyte-derived dendritic cells. J Immunol 177:2080–2087PubMedGoogle Scholar
  23. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJF (2011) Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 54:1127–1135PubMedCrossRefGoogle Scholar
  24. Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG (2000) Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med 6:278–282PubMedCrossRefGoogle Scholar
  25. Russ HA, Ravassard P, Kerr-Conte J, Pattou R, Efrat S (2009) Epithelial mesenchymal transition in cells expanded in vitro from lineage-traced adult human pancreatic beta cells. PLoS One 4:e6417PubMedCrossRefGoogle Scholar
  26. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228–234PubMedCrossRefGoogle Scholar
  27. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 26:212–222PubMedCrossRefGoogle Scholar
  28. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, Garcai-Ocana A, Feili-Hariri M (2009) Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 32:116–124PubMedCrossRefGoogle Scholar
  29. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L (2005) Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106:419–427PubMedCrossRefGoogle Scholar
  30. Sordi V, Melzi R, Mercalli A, Formicola R, Doglioni C, Tiboni F, Ferrari G, Nano R, Chwalek K, Lammert E, Bonifacio E, Borg D, Piermonti L (2010) Mesenchymal cells appearing in pancreatic tissue culture are bone marrow-derived stem cells with the capacity to improve transplanted islet function. Stem Cells 1:140–151Google Scholar
  31. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24:74–85PubMedCrossRefGoogle Scholar
  32. Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, Jorgensen C, Le Blanc K, Luyten F, McGonagle D, Martin I, Bocelli-Tyndall C, Pennesi G, Pistoia V, Pitzalis C, Uccelli A, Wulffraat N, Feldmann M (2007) Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 9:301PubMedCrossRefGoogle Scholar
  33. Urban VS, Kiss J, Kovacs J, Gocza E, Vas V, Monostori E, Uher F (2008) Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 26:244–253PubMedCrossRefGoogle Scholar
  34. Wu XH, Liu CP, Xu KF, Mao XD, Zhu J, Jiang JJ, Cui D, Zhang M, Xu Y, Liu C (2007) Reversal of hyperglycemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. World J Gastroenterol 13:3342–3349PubMedGoogle Scholar
  35. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, Yarmush ML (2010) Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 19:667–679PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Brigham & Women’s Hospital, Transplantation Research Center, EBRCBostonUSA

Personalised recommendations